• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Venetoclax for arsenic-resistant acute promyelocytic leukaemia.

作者信息

Wang Qian Qian, Wang Hua-Feng, Zhao Jian-Zhi, Naranmandura Hua, Jin Jie, Zhu Hong-Hu

机构信息

Department of Haematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.

Zhejiang Province Key Laboratory of Haematology Oncology Diagnosis and Treatment.

出版信息

Br J Haematol. 2022 Jun;197(5):e58-e60. doi: 10.1111/bjh.18061. Epub 2022 Feb 17.

DOI:10.1111/bjh.18061
PMID:35176809
Abstract
摘要

相似文献

1
Venetoclax for arsenic-resistant acute promyelocytic leukaemia.维奈克拉用于治疗对砷耐药的急性早幼粒细胞白血病。
Br J Haematol. 2022 Jun;197(5):e58-e60. doi: 10.1111/bjh.18061. Epub 2022 Feb 17.
2
Venetoclax overcomes resistance to all-trans retinoic acid in a variant acute promyelocytic leukemia with TNRC18::RARA fusion.维奈托克克服了具有 TNRC18::RARA 融合的变异型急性早幼粒细胞白血病对全反式维甲酸的耐药性。
Mol Carcinog. 2024 Apr;63(4):553-557. doi: 10.1002/mc.23671. Epub 2023 Dec 22.
3
Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.具有新型NAB2::RARA融合基因的变异型急性早幼粒细胞白血病表现出对全反式维甲酸和三氧化二砷的临床敏感性。
Br J Haematol. 2023 Aug;202(4):893-896. doi: 10.1111/bjh.18907. Epub 2023 Jun 6.
4
Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: A case report.伴有 RARA-LBD 区域突变的复发/难治性急性早幼粒细胞白血病经 venetoclax 挽救治疗：一例报告。
Medicine (Baltimore). 2021 Dec 3;100(48):e28076. doi: 10.1097/MD.0000000000028076.
5
Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia.三氧化二砷与全反式维甲酸治疗新诊断的儿童急性早幼粒细胞白血病
Leuk Lymphoma. 2021 May;62(5):1267-1270. doi: 10.1080/10428194.2020.1856832. Epub 2021 Jan 13.
6
Fertility and parenthood in patients with acute promyelocytic leukemia treated with Arsenic Trioxide and All-Trans retinoic acid.接受三氧化二砷和全反式维甲酸治疗的急性早幼粒细胞白血病患者的生育能力与为人父母情况
Blood Cancer J. 2024 Jan 19;14(1):14. doi: 10.1038/s41408-024-00984-1.
7
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.澳大利亚和新西兰白血病与淋巴瘤组（ALLG）APML4研究中三氧化二砷用于急性早幼粒细胞白血病诱导缓解和巩固治疗：一项非随机2期试验
Lancet Haematol. 2015 Sep;2(9):e357-66. doi: 10.1016/S2352-3026(15)00115-5. Epub 2015 Aug 20.
8
Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe.线粒体DNA含量高于正常水平与急性早幼粒细胞白血病更好的预后相关？也许吧。
Br J Haematol. 2023 Jan;200(2):126-127. doi: 10.1111/bjh.18534. Epub 2022 Nov 7.
9
Severe Wernicke encephalopathy and acute pancreatitis due to all-trans-retinoic acid and arsenic trioxide during treatment of acute promyelocytic leukaemia: a case report.全反式维甲酸和三氧化二砷治疗急性早幼粒细胞白血病期间导致的严重韦尼克脑病和急性胰腺炎：一例报告
J Int Med Res. 2020 Sep;48(9):300060520959487. doi: 10.1177/0300060520959487.
10
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.三氧化二砷和全反式维甲酸治疗所有风险组急性早幼粒细胞白血病（AML17）：一项随机、对照、3 期临床试验的结果。
Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14.

引用本文的文献

1
PML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias.早幼粒细胞白血病伴维甲酸受体α（PML::RARα）阳性的髓系细胞表现出代谢改变，这些改变可作为治疗耐药/复发急性早幼粒细胞白血病的靶点。
Leukemia. 2025 Sep 10. doi: 10.1038/s41375-025-02738-9.
2
[The cure for acute promyelocytic leukemia and China's contributions].[急性早幼粒细胞白血病的治疗及中国的贡献]
Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):377-384. doi: 10.3760/cma.j.cn121090-20250307-00119.
3
Venetoclax combined with ATRA shows promising therapeutic potential for TFG:: RARA variant APL: a case report.
维奈托克联合全反式维甲酸对TFG::RARA变异型急性早幼粒细胞白血病显示出有前景的治疗潜力：一例病例报告
Front Oncol. 2025 May 2;15:1529640. doi: 10.3389/fonc.2025.1529640. eCollection 2025.
4
Venetoclax for an ATRA and ATO resistance acute promyelocytic leukemia patient with fusion gene.维奈托克用于一名伴有融合基因的全反式维甲酸和三氧化二砷耐药的急性早幼粒细胞白血病患者。
Leuk Res Rep. 2024 Sep 24;22:100482. doi: 10.1016/j.lrr.2024.100482. eCollection 2024.
5
Spinal myeloid sarcoma presenting as initial symptom in acute promyelocytic leukemia with a rare cryptic fusion gene: a case report and literature review.以罕见隐匿性融合基因为首发症状的急性早幼粒细胞白血病合并脊髓髓肉瘤：一例报告及文献复习
Front Oncol. 2024 May 21;14:1375737. doi: 10.3389/fonc.2024.1375737. eCollection 2024.
6
Treatment of a Patient with Acute Promyelocytic Leukemia with Multiple Isolated Relapses in the Central Nervous System: A Case Report and Mini-Review of the Literature.一名中枢神经系统多次孤立复发的急性早幼粒细胞白血病患者的治疗：病例报告及文献综述
Case Rep Hematol. 2024 May 3;2024:5593775. doi: 10.1155/2024/5593775. eCollection 2024.
7
Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia in the Era of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO).全反式维甲酸（ATRA）和三氧化二砷（ATO）时代急性早幼粒细胞白血病的造血干细胞移植
Cancers (Basel). 2023 Aug 15;15(16):4111. doi: 10.3390/cancers15164111.
8
The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions.2023年急性早幼粒细胞白血病的治疗：模式、进展与未来方向。
Front Oncol. 2023 Jan 18;12:1062524. doi: 10.3389/fonc.2022.1062524. eCollection 2022.
9
Hyperthermia promotes degradation of the acute promyelocytic leukemia driver oncoprotein ZBTB16/RARα.高热促进急性早幼粒细胞白血病驱动癌蛋白 ZBTB16/RARα 的降解。
Acta Pharmacol Sin. 2023 Apr;44(4):822-831. doi: 10.1038/s41401-022-01001-6. Epub 2022 Oct 10.
10
Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA.在携带ZBTB16-RARA的变异型急性早幼粒细胞白血病中使用低剂量维奈克拉进行分化治疗。
Br J Haematol. 2022 Dec;199(5):768-771. doi: 10.1111/bjh.18476. Epub 2022 Sep 28.